Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Survey on Interdisciplinary Management of Cardiotoxicity in Outpatient Sett
Author(s): Silvio Quick , Lorena Payo-Anez , Clara Marx Casimiro de Almeida , et al Added: 5 months ago

Guidelines & Statements

Imaging & Diagnostics
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations
POTS-associated Conditions and Management Strategies
Author(s): Alexis Cutchins , Svetlana Blitshteyn , Rebecca Steinberg Added: 1 year ago
Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder that presents with positional tachycardia, amongst many other symptoms. Evidence for treatment options remains limited, and there are a multitude of associated conditions with overlapping symptoms which can make the diagnosis and management of POTS a difficult experience for providers and patients alike.This broadcast… View more

Electrophysiology & Arrhythmia

COVID-19
Erratum: Causal Characteristics of Immune Cells
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 2 months ago
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 3 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
Immune Cell Traits and Aortic Dissection: A Mendelian Randomisation Study
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 3 months ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ACC 25 Late-Breaking Discussion: The API-Cat Study
Author(s): Harriette Van Spall , Isabelle Mahé Added: 3 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the… View more

Anticoagulation

Vascular Disease and Surgery
Research Area(s) / Expertise:

Cardio-oncology

Heart Failure

 Job title: Assistant Professor
Dr Giselle Melendez is anAssistant Professor atWake Forest University School of Medicine, Winston-Salem, US.Commencing her scientific career at the University of South Carolina School of Medicine, Dr. Melendez focused on molecular mediators of myocardial extracellular matrix remodeling and heart failure. Notably, her research uncovered vital insights into inflammatory cytokines TNF-α, IL-6, and… View more
Ian Paterson
Job title: Professor
Dr Ian Paterson is a Professor of Medicine in the Division of Cardiology at the University of Alberta. He completed his Cardiology training and an Echocardiography Fellowship at the McGill University, followed by a Cardiovascular MRI Fellowship at the National Institutes of Health. Dr Paterson is also the Academic and Research Director of Cardiovascular Magnetic Resonance at the University of… View more